Peter S. Greenleaf
Independent ChairmanMr. Peter S. Greenleaf, M.B.A., is Director of Altimmune, Inc. from November 2, 2026. Mr. Greenleaf is an Independent Chairman of Pelthos Therapeutics Inc. He is Director of Pelthos Therapeutics Inc. from July 1, 2025. He serves as Non Executive Director at Revolo Biotherapeutics Limited. He was Chief Executive Officer and Director of Aurinia Pharmaceuticals Inc. since April 29, 2019 until March 2026 and was its President until March 2026. He is Consultant of Aurinia Pharmaceuticals Inc. from March 2026. He was President of Aurinia Pharmaceuticals Inc. from April 29, 2019 until October 2024. He is Director at NVN Liquidation Inc. He serves as Director at ValenzaBio, Inc. since August 2022. Mr. Greenleaf had been a Director at Antares Pharma, Inc. since December 13, 2018 until May 24, 2022. He served as a Director of EyeGate Pharmaceuticals, Inc. since July 10, 2018 until January 3, 2020. He was Chief Executive Officer of Cerecor Inc. (Cerecor Pharmaceuticals, Inc. (now Avalo Therapeutics, Inc.)) since March 28, 2018 until April 15, 2019. He serves as a Member of Advisory Board at Petrichor Healthcare Capital Management LP. He served as the Chairman and Chief Executive Officer of Sucampo Pharmaceuticals, Inc. since January 1, 2016 and since March 03, 2014 until February 2018 respectively. Mr. Greenleaf was an Executive Director at Sucampo Pharmaceuticals, Inc. from March 03, 2014 to February 2018. He served as Chief Executive Officer of Histogenics Corporation from June 10, 2013 to February 28, 2014 and served as its President. He served as President of MedImmune Ventures from January 2010 to June 2013. He served as President of MedImmune Limited since February 2010. He served as the Senior Vice President of marketing and sales of Medimmune Inc., since May 2006 and its Senior Vice President of Commercial Operations, Corporate Development & Strategy and MedImmune Ventures Inc. He served as Chief Commercial Officer of MedImmune. He initially joined MedImmune LLC in 2006 until 2010 as Senior Vice President of Commercial Operations. He served as the Vice President of the Gastroenterology Franchise Centocor, Inc. (now Jansen Biotechnology, Johnson & Johnson). He served as a Director of Synlogic, Inc. until August 28, 2017. Mr. Greenleaf joined Centocor's Cardiovascular Division in 1998 and moved into the immunology business, holding a number of postions with increasing responsibility in sales and marketing. He served in sales and marketing capacities at Boehringer Mannheim Corporation and US Healthcare, Inc. He has also held senior commercial roles at Centocor Biotech, Inc. (now Jansen Biotechnology, Johnson & Johnson) from 1998 to 2006 and Boehringer Mannheim G.m.b.H. (now Roche Holdings) from 1996 to 1998. He serves as Chairman of Maryland Venture Fund Authority. He had been a Director of Cerecor Inc. since May 15, 2017 until February 13, 2020. He serves as Chairman of BioDelivery Sciences International, Inc. since May 17, 2018. From 2006 to 2013. Mr. Greenleaf was employed by Medlmmune LLC, the global biologics arm of AstraZeneca, where he served as President. He previously served on the boards of PhARMA. He has been a Director of Mirna Therapeutics, Inc. since February 1, 2016 to August 2017. He served as Director of Savara Inc. until April 27, 2017. He was a Director of Mast Therapeutics, Inc., since November 2015 to April 2017. He is also a Member of The Board of Directors of the Biotechnology Industry Organization (BIO), where he serves on the Governing Boards of the Emerging Companies and Health Sections. He served as Director of Savara Inc. He served as a Director of Corridor Pharmaceuticals, Inc. from 2010 to 2013; Takeda Vaccines (Montana), Inc.; Histogenics Corporation from June 2013 to March 2014; LigoCyte Pharmaceuticals, Inc. from 2010 to 2011; Melinta Therapeutics, Inc., (formerly known as Rib-X Pharmaceuticals, Inc.) since January 20, 2010 and University of Maryland Baltimore Foundation, Inc. Mr. Greenleaf has an M.B.A. from St. Joseph's University and a B.S. degree from Western Connecticut State University. Mr. Greenleaf previously partnered with Governor Martin O’Malley to chair the Maryland Venture Fund Authority. Mr. Peter S. Greenleaf, M.B.A., is Director of Pelthos Therapeutics Inc. from July 1, 2025. He serves as Non Executive Director at Revolo Biotherapeutics Limited. He has been Chief Executive Officer and Director of Aurinia Pharmaceuticals Inc. since April 29, 2019 and serves as its President. He was President of Aurinia Pharmaceuticals Inc. from April 29, 2019 until October 2024. He is Director at NVN Liquidation Inc. He serves as Director at ValenzaBio, Inc. since August 2022. Mr. Greenleaf had been a Director at Antares Pharma, Inc. since December 13, 2018 until May 24, 2022. He served as a Director of EyeGate Pharmaceuticals, Inc. since July 10, 2018 until January 3, 2020. He was Chief Executive Officer of Cerecor Inc. since March 28, 2018 until April 15, 2019. He serves as a Member of Advisory Board at Petrichor Healthcare Capital Management LP. He served as the Chairman and Chief Executive Officer of Sucampo Pharmaceuticals, Inc. since January 1, 2016 and since March 03, 2014 until February 2018 respectively. Mr. Greenleaf was an Executive Director at Sucampo Pharmaceuticals, Inc. from March 03, 2014 to February 2018. He served as Chief Executive Officer of Histogenics Corporation from June 10, 2013 to February 28, 2014 and served as its President. He served as President of MedImmune Ventures from January 2010 to June 2013. He served as President of MedImmune Limited since February 2010. He served as the Senior Vice President of marketing and sales of Medimmune Inc., since May 2006 and its Senior Vice President of Commercial Operations, Corporate Development & Strategy and MedImmune Ventures Inc. He served as Chief Commercial Officer of MedImmune. He initially joined MedImmune LLC in 2006 until 2010 as Senior Vice President of Commercial Operations. He served as the Vice President of the Gastroenterology Franchise Centocor, Inc. (now Jansen Biotechnology, Johnson & Johnson). He served as a Director of Synlogic, Inc. until August 28, 2017. Mr. Greenleaf joined Centocor's Cardiovascular Division in 1998 and moved into the immunology business, holding a number of postions with increasing responsibility in sales and marketing. He served in sales and marketing capacities at Boehringer Mannheim Corporation and US Healthcare, Inc. He has also held senior commercial roles at Centocor Biotech, Inc. (now Jansen Biotechnology, Johnson & Johnson) from 1998 to 2006 and Boehringer Mannheim G.m.b.H. (now Roche Holdings) from 1996 to 1998. He serves as Chairman of Maryland Venture Fund Authority. He had been a Director of Cerecor Inc. since May 15, 2017 until February 13, 2020. He serves as Chairman of BioDelivery Sciences International, Inc. since May 17, 2018. From 2006 to 2013. Mr. Greenleaf was employed by Medlmmune LLC, the global biologics arm of As
Positions
- Company NamePelthos Therapeutics Inc.Stock CodePTHSPositionIndependent Chairman
- Company NameAurinia Pharmaceuticals Inc.Stock CodeAUPHPositionConsultantColleagues
- KCKevin C. TangChairman & CEO
- SPStephen P. RobertsonChief Legal Officer, Corporate Secretary & Chief Compliance Officer
- MSMichael S. HearneChief Financial Officer
- RCRyan ColeChief Operating Officer
- JAJeffrey Allen BaileyIndependent Director
- CACraig A. JohnsonLead Independent Director
- KLKathy L. GoetzIndependent Director
- TSTina S. NovaIndependent Director
